<DOC>
	<DOCNO>NCT00245414</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety Pegasys® 180μg subcutaneous ( s.c. ) injection interferon ( IFN ) -treated IFN-untreated chronic hepatitis C patient except infected genotype 1b hepatitis C virus ( HCV ) high viral load ( ≥ 100 KIU/mL ) . In addition , study explore efficacy safety Pegasys® 180μg s.c. injection give 2 different period 24 48 week IFN-untreated chronic hepatitis C patient .</brief_summary>
	<brief_title>Trial Pegasys® Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Quantitative serum HCVRNA positive except high viral load genotype 1b ( ≥ 100 KIU/mL ) Observation serum ALT elevation upper limit normal Chronic hepatitis evaluate negative result ( &lt; 0 ) calculate method `` formula discrimination chronic hepatitis liver cirrhosis . '' Observation white blood cell ≦ 3000/mm3 ; neutrophil ≦ 1500/mm3 ; platelet ≦ 90,000/mm3 ; hemoglobin ≦ 10 g/dL . Observation follow situation disease : severe renal disease , hepatitis B coinfection , decompensated liver disease , liver cirrhosis , hepatocellular carcinoma , poorly control psychiatric disease , seizure disorder , immunologically mediated disease , severe cardiac disease , poorly uncontrolled hypertension , poorly control diabetes , chronic pulmonary disease , retinopathy , malignant tumor , organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>